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AbstrACt
Introduction The 30-item Geriatric Depression Scale 
(GDS-30) and the shorter GDS-15, GDS-5 and GDS-4 
are recommended as depression screening tools for 
elderly individuals. Existing meta-analyses on the 
diagnostic accuracy of the GDS have not been able to 
conduct subgroup analyses, have included patients 
already identified as depressed who would not be 
screened in practice and have not accounted for 
possible bias due to selective reporting of results from 
only better-performing cut-offs in primary studies. 
Individual participant data meta-analysis (IPDMA), 
which involves a standard systematic review, then a 
synthesis of individual participant data, rather than 
summary results, could address these limitations. 
The objective of our IPDMA is to generate accuracy 
estimates to detect major depression for all possible 
cut-offs of each version of the GDS among studies 
using different reference standards, separately and 
among participant subgroups based on age, sex, 
dementia diagnosis and care settings. In addition, we 
will use a modelling approach to generate individual 
participant probabilities for major depression based 
on GDS scores (rather than a dichotomous cut-off) 
and participant characteristics (eg, sex, age, dementia 
status, care setting).
Methods and analysis Individual participant data 
comparing GDS scores to a major depression diagnosis 
based on a validated structured or semistructured 
diagnostic interview will be sought via a systematic 
review. Data sources will include Medline, Medline In-
Process & Other Non-Indexed Citations, PsycINFO and 
Web of Science. Bivariate random-effects models will be 
used to estimate diagnostic accuracy parameters for each 
cut-off of the different versions of the GDS. Prespeciied 
subgroup analyses will be conducted. Risk of bias will 
be assessed with the Quality Assessment of Diagnostic 
Accuracy Studies-2 tool.
Ethics and dissemination The indings of this study will 
be of interest to stakeholders involved in research, clinical 
practice and policy.
PrOsPErO registration number CRD42018104329.
strengths and limitations of this study
 Ź This study will use individual participant data to 
estimate diagnostic accuracy for all relevant cut-
off scores of the different versions of the Geriatric 
Depression Scale. Using data from all participants 
at each cut-off score will overcome limitations re-
lated to selective cut-off reporting in primary study 
publications.
 Ź This study will conduct analyses that exclude pa-
tients with current diagnoses of depression or who 
are undergoing mental health treatment, including 
antidepressants, at the time of study enrolment, 
as these patients would not be screened in clinical 
practice. This will overcome potential bias in prima-
ry diagnostic test accuracy studies where these pa-
tients are often included.
 Ź This study will include subgroup analyses of diag-
nostic accuracy across different reference standards 
and by participant characteristics (eg, sex, age, de-
mentia status, care setting).
 Ź A potential limitation is that the success of the study 
depends on the ability to obtain the relevant individ-
ual participant data and to avoid selective availabil-
ity of studies with better or worse accuracy results. 
We do not know the proportion of eligible datasets 
that will be possible to include in the study.
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bACkgrOund 
Major depression is present in 5%–10% of the geri-
atric population internationally.1 2 Effective treatments 
for depression are available, but identification is often 
haphazard. Physicians may fail to recognise up to half 
of all patients with depression, and most patients with 
depression do not receive minimally adequate care.3 4 
At the same time, there is a high rate of overdiagnosis 
and overtreatment, and the majority of patients who are 
treated do not meet diagnostic criteria.5–7 Diagnosis of 
elderly individuals can be particularly difficult for clini-
cians due to factors such as cognitive impairments, social 
stigma, medical comorbidity and atypical or vague clin-
ical presentation.1 8 9
Some Canadian and international geriatric care organ-
isations recommend screening elderly adults for depres-
sion,10–13 but the Canadian Task Force on Preventive 
Health Care (CTFPHC), for instance, does not recom-
mend depression screening, including for geriatric 
individuals.14 The CTFPHC has expressed concern that 
published studies may overstate the accuracy of depres-
sion screening tools and that screening could lead to high 
rates of false positive tests, and still not improve depres-
sion outcomes.14
The 30-item Geriatric Depression Scale (GDS-30) 
and the GDS-15, GDS-5 and GDS-4, which are 15-item, 
5-item and 4-item subsets of the GDS-30, are commonly 
recommended as depression screening tools for elderly 
individuals.15–17 As with other depression screening 
tools, primary studies on the diagnostic accuracy of the 
different versions of the GDS have been limited by (1) 
small samples; (2) the selective reporting of results for 
cut-offs when they perform well in a given sample, but not 
when they perform poorly; (3) the inclusion of patients 
already known by clinicians to have depression and (4) the 
inability to conduct subgroup analyses (eg, different age 
groups, dementia diagnosis, care settings) due to small 
sample sizes. Conventional meta-analyses of the GDS or 
short versions of the GDS that have synthesised published 
summary data have not been able to conduct subgroup 
analyses or exclude already diagnosed patients,15 16 18 and 
concerns have been raised about bias in these meta-anal-
yses due to selective cut-off reporting in primary studies 
that could not be addressed.18
Individual participant data meta-analysis (IPDMA), 
which involves a standard systematic review, followed by 
synthesis of actual participant data from primary studies, 
rather than aggregating summary data, can address these 
problems by including actual participant data from all 
studies.19 20 In the context of evaluating the diagnostic 
accuracy of depression screening tools, IPDMA has three 
major advantages compared with conventional meta-anal-
yses. First, for the conventional binary screening approach, 
IPDMA can address bias from the selective publication of 
diagnostic accuracy results for well-performing cut-offs 
from small studies since accuracy can be evaluated across 
all relevant cut-offs for all participants. Second, IPDMA 
allows the appropriate exclusion of already diagnosed or 
already treated patients when primary studies have data 
on existing diagnoses and treatment. Third, an IPDMA 
with large numbers of participants and major depression 
cases would allow subgroup analyses by study-level factors 
(eg, study setting, risk of bias factors) and individual 
factors that may influence screening accuracy (eg, age, 
sex, dementia diagnosis). Finally, a large IPD database 
would allow the development of a predictive algorithm 
to generate estimates of the probability of having major 
depression based on participant characteristics and actual 
GDS scores, rather than binary classifications of individ-
uals as simply negative or positive based on screening 
results. This is important because, for instance, an indi-
vidual with a score of 0 on the GDS-30 may have a lower 
likelihood of having depression than an individual with 
a substantially higher, but sub-cut-off, score of 10. Using 
a dichotomous cut-off method, however, both would be 
classified as negative screens and assigned the same prob-
ability of having depression.
One of the downsides of IPDMAs is that they are 
resource intensive. In addition, if the primary datasets 
obtained are not representative of all primary studies, the 
IPDMA could be biased.19–22 In a previous IPDMA of the 
Patient Health Questionnaire-9 (PHQ-9) screening tool, 
which was the first IPDMA of the diagnostic accuracy of 
a depression screening tool,23 we were able to synthesise 
58 of 72 eligible primary datasets (17 357 participants, 
2312 major depression cases). This suggests that investi-
gators are generally able and willing to provide primary 
data from studies of the diagnostic accuracy of depression 
screening tools for use in IPDMA. A preliminary PubMed 
search for the GDS verified the existence of enough 
primary studies (more than 100 potentially eligible data-
sets that appear to have at least 30 000 participants, 4000 
cases) to make IPDMA feasible for the GDS.
Thus, the objectives of this IPDMA are to evaluate the 
diagnostic accuracy of the GDS-30, GDS-15, GDS-5 and 
GDS-4 among studies using different reference standards, 
separately; among participant subgroups based on age, 
sex, dementia diagnosis and care settings; and excluding 
participants identified as already diagnosed or treated 
for depression. Furthermore, a prediction model will be 
generated.
MEthOds And AnAlysIs
This systematic review has been funded by the Cana-
dian Institutes of Health Research (Funding Reference 
Number PJT-156365).
The IPDMA has been designed and will be conducted in 
accordance with best-practice standards as elaborated in 
the Cochrane Handbook for Systematic Reviews of Diag-
nostic Test Accuracy (DTA)24 and other key sources.19 20 25 
Results will be reported in accordance with the Preferred 
Reporting Items for Systematic Reviews and Meta-Anal-
yses of DTA Studies (PRISMA-DTA) statement and the 
PRISMA-IPD statement.26 27 The IPDMA protocol does 
not deviate substantively from previous IPDMA protocols 
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that we have developed and published for other depres-
sion screening tools.23 28 29
sources of evidence
The search strategy was developed by a medical librarian 
and was adapted from a search strategy developed for a 
similar systematic review to obtain datasets for IPDMA 
of the PHQ-9 depression screening tool,23 which was 
peer reviewed using the Peer Review of the Electronic 
Search Strategy standard.30 The search strategy is also 
similar to strategies that we have used for systematic 
reviews and IPDMA of the Hospital Anxiety and Depres-
sion Scale and Edinburgh Postnatal Depression Scale.28 29
We will search Medline, Medline In-Process & Other 
Non-Indexed Citations, PsycINFO (OvidSP platform) 
and Web of Science (Web of Knowledge platform). The 
Medline search strategy for the GDS was validated by 
testing against already identified publications from our 
preliminary search. The strategy was then adapted for 
PsycINFO and Web of Science. We limited our search 
strategy to these databases based on research showing 
that adding other databases (eg, EMBASE) when the 
Medline search is highly sensitive does not identify 
additional eligible studies.31 The Cochrane Handbook 
for Systematic Reviews of DTA24 suggests combining 
concepts of the index test and the target conditions, 
but this was redundant for depression screening tools as 
these tests are limited to testing for depression. Thus, the 
search strategy for electronic databases was composed 
of two concepts: the index test of interest and studies of 
screening accuracy. There are no published search hedges 
designed specifically for mental health screening, but key 
articles were consulted in developing search terms.32–34 
See online supplementary file 1 for detailed information 
on searches. To supplement electronic searches, we will 
search reference lists of included publications and rele-
vant reviews, conduct a related articles search using the 
PubMed ‘related articles’ feature, and query authors of 
included studies for unpublished studies. Search results 
will be uploaded into the citation management database 
RefWorks (RefWorks-COS, Bethesda, Maryland, USA), 
and the RefWorks duplicate check function will be used to 
identify citations retrieved from multiple sources. Unique 
citations will then be uploaded into the systematic review 
programme DistillerSR (Evidence Partners, Ottawa, 
Canada), and DistillerSR will be used to store and track 
search results and to track results of the review process.
selection of eligible studies
To conduct the meta-analysis, we will seek primary 
datasets that allow us to compare GDS scores to major 
depression diagnostic status. Datasets from articles 
in any language will be sought for inclusion if they 
compare results from any version of the GDS to diag-
noses of major depressive disorder (MDD) or major 
depressive episode (MDE) made with a validated diag-
nostic interview, administered within 2 weeks of the GDS 
and based on Diagnostic and Statistical Manual (DSM) 
or International Classification of Diseases criteria (ICD), 
which are similar to DSM criteria and generally used 
outside of North America.
The 2-week criterion was set because that is the duration 
of symptoms required for a diagnosis of major depres-
sion. Datasets where some participants were administered 
the screening tool within 2 weeks of the diagnostic inter-
view and some participants were not will be included if 
the original data allows us to identify and select eligible 
participants. Most primary studies use MDD as the refer-
ence standard, but some may use MDE, which is identical 
with respect to the symptoms of depression, but does not 
exclude participants with psychotic disorders or a history 
of manic episodes. If both are available, we will record 
both and prioritise DSM over ICD and MDE over MDD 
in analyses. Data from studies where all participants are 
known to have psychiatric diagnoses, have been referred 
for mental health evaluation or are undergoing treat-
ment for depression will be excluded, with the excep-
tion of participants treated for substance use disorders, 
for whom depression screening may be considered. The 
coding manual for inclusion and exclusion decisions is 
shown in online supplementary file 2.
Two investigators will review articles independently 
for eligibility. If either reviewer determines that a study 
may be eligible based on title or abstract review, a full-
text article review will be completed. Disagreement 
between reviewers after full-text review will be resolved 
by consensus, including a third investigator as necessary. 
Translators will be used to evaluate titles/abstracts and 
articles for languages other than those for which team 
members are fluent. See online supplementary file 3 for a 
preliminary PRISMA flow of studies figure.
transfer of data and data management
Authors of studies containing datasets that meet inclu-
sion criteria will be contacted to invite them to contribute 
primary data for inclusion. Data will only be used from 
studies that received ethics approval and all data that 
are transferred will be properly de-identified prior to 
transfer. Participant data will be cleaned and coded for 
uniformity across datasets using an already developed 
codebook, similar to codebooks used in our previous 
IPDMAs.23 28 29 Actual data coding and transfer from 
original studies into the IPD database will be done by a 
supervised staff or trainee member of the team. Partic-
ipant characteristics and screening accuracy results for 
each study using the cleaned datasets will be compared 
with those from the original datasets to identify any 
potential discrepancies.
In addition to obtaining original participant-level data, 
data will also be extracted from the published articles of 
included studies. We will cross-check the published data 
with the original participant-level data obtained from 
each dataset and any inconsistencies will be discussed 
with the original authors. Corrections will be made as 
necessary.
 o
n
 11 D
ecem
ber 2018 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-026598 on 4 December 2018. Downloaded from 
4 Benedetti A, et al. BMJ Open 2018;8:e026598. doi:10.1136/bmjopen-2018-026598
Open access 
Quality assessment
Two reviewers will independently use the Quality Assess-
ment of Diagnostic Accuracy Studies-2 (QUADAS-2) 
tool35 to assess risk of bias in primary studies. QUADAS-2 
incorporates assessments of risk of bias across four core 
domains: participant selection, the index test, the refer-
ence standard, and the flow and timing of assessments. 
Two reviewers will independently assess risk of bias, and 
any discrepancies will be resolved by consensus.
data analysis
Analyses will estimate sensitivity and specificity separately 
at each cut-off by bivariate random-effects meta-analysis 
models as described in Riley et al.36 For each GDS version, 
we will fit these models, estimated via Gauss-Hermite 
adaptive quadrature, for the full range of plausible GDS 
cut-off values.36 This approach models sensitivity and spec-
ificity simultaneously and accounts for the precision of 
estimates within studies.36 Data from all included primary 
studies will be analysed simultaneously with a random-ef-
fects model as sensitivity and specificity are assumed 
to vary across primary studies. We will also construct a 
pooled receiver operating characteristic curve and iden-
tify the optimal cut-off.36 We will compare results that only 
include datasets that allow the exclusion of patients diag-
nosed with depression or receiving depression treatment 
(including antidepressants with reason unspecified) with 
results that also include studies where these data are not 
available. For assessment of each version, we will include 
studies that report total scores for the specific GDS version 
or individual GDS item scores from longer versions of the 
GDS which could be used to calculate total scores for the 
shorter version. We will consider imputation if a large 
part of data is missing.
In a previous IPDMA with the PHQ-9,37 we found that 
reference standards appeared to perform differently. The 
Mini International Neuropsychiatric Interview (MINI) is 
fully structured, but was designed for very rapid admin-
istration and described as its authors as being overinclu-
sive as a result. We found that, controlling for depressive 
symptom scores, the MINI classified approximately twice 
as many participants with major depression as other fully 
structured interviews.38 39Compared with semistructured 
interviews, which are intended to be done by experienced 
diagnosticians and involve some clinical judgement (eg, 
Structured Clinical Interview for DSM Disorders) fully 
structured interviews (MINI excluded), diagnosed more 
participants with low symptom levels as depressed and 
fewer participants with higher symptom levels. Fully 
structured interviews can be delivered by lay interviewers 
and are intended to achieve a high level of standardisa-
tion, but may sacrifice accuracy.40–43 Thus, we will assess 
possible differences and evaluate sensitivity and speci-
ficity separately by reference standard.
In secondary analyses, to the extent that there are 
sufficient data, we will investigate subgroups according 
to age, sex, dementia status and severity, dementia 
subtype, number of medical comorbidities (with specific 
comorbidities integrated to the extent possible), care 
setting and risk of bias. QUADAS-2 factors that will be 
considered include patient selection factors, blinding 
of reference standard to index test results, and timing 
between administration of index test and reference stan-
dard (eg, 0–7 days, 7–14 days). Additionally, a subgroup 
analysis will be conducted that includes only data from 
countries listed as ‘very high development’ on the United 
Nation’s Human Development Index.44
If there is a sufficient number of studies with published 
diagnostic accuracy data for major depression that are 
eligible but do not provide data, studies included in the 
IPDMA will be compared with eligible studies that do 
not provide data in terms of sensitivity and specificity, 
using published summary data from the studies that do 
not provide data. Depending on the number of missing 
studies, a sensitivity analysis may also be conducted that 
includes aggregate summary estimates of sensitivity and 
specificity from the studies that do not provide IPD in 
the main meta-analysis, along with data from studies that 
contribute to the IPDMA.36 If there are a large number of 
studies that do not contribute primary data, this analysis 
may become the primary analysis.
Clinical predictive models have not been used previ-
ously to generate individualised probabilities that an indi-
vidual has major depression based on screening tool scores 
and participant characteristics. There is a rich tradition 
of using predictive models for risk scores or classifying 
patients based on diagnostic tests, and our approach will 
build on those traditions.45–50 To do this, we will develop 
binary predictive models that use GDS scores as well as 
key participant characteristics (eg, sex, age, dementia 
status, care setting) to estimate the probability and asso-
ciated 95% CI that an individual has major depression. 
We will estimate logistic mixed models and then integrate 
over the distribution of the random effects as described 
in Pavlou et al and Skrondal et al.51 52 Continuous vari-
ables (GDS score and age) will be modelled using flexible 
semiparametric methods (eg, regression splines). We will 
consider the inclusion of interaction terms. The models 
will be evaluated in terms of their overall performance 
(Nagelkerke’s R2, Brier score), calibration (eg, slope of 
linear predictor; are average, low and high predictions 
correct) and discrimination (eg, c-statistic; discrimination 
slope: can we separate subjects with and without major 
depression).45 46 Validation with the same subjects used 
to develop a model results in overly optimistic perfor-
mance. We will assess internal validation via the boot-
strap method, which has been shown to be preferable to 
split sample validation approaches.47 Although there are 
advantages to external validation, given the wide range 
of study populations that we will be using, it would be 
unlikely that there would be another comparable dataset 
large enough for validation. Thus, assessment of internal 
validity via bootstrapping will allow us to understand 
how our model may perform in a clinical setting, and by 
adjusting our regression coefficients for optimism, the 
performance of our model will be as accurate as possible. 
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In sensitivity analyses, we will explore including each item 
from the GDS questionnaires as a separate predictor vari-
able, rather than only the total score.
Patient and public involvement
Patients and members of the public were not involved in 
the study.
EthICs And dIssEMInAtIOn
Only individual studies that obtained ethical clearance 
and informed consent will be included. Only anonymised 
data will be provided by the investigators of the original 
studies.
The main outcomes of the IPDMA reflect knowledge 
that will influence future research, clinical practice and 
policy. Strategies for effective dissemination and specific 
outputs will be based on research showing how to best 
tailor research outputs to different user groups,53–58 
including research on improving the usefulness of 
reports of systematic review and meta-analyses for health-
care managers and policy-makers.56 58 Dissemination will 
include publication of results in high-impact medical jour-
nals with open access, as well as presentations in seminars 
and symposia to policy-makers, healthcare providers and 
researchers at national and international conferences.
If the predictive model performs well, a free and easy-
to-use online calculation tool will be created to incorpo-
rate individual characteristics into accuracy estimates and 
provide users of our research with probabilities that indi-
vidual patients have depression based on their GDS score 
and key characteristics. The calculator will be similar to 
other successful tools, such as the FRAX Fracture Risk 
Assessment Tool (http://www. shef. ac. uk/ FRAX/ index. 
aspx). The tool that will be made from the results of this 
study will be modelled on this tool and presented with 
tablet and app versions.
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